ES3064009T3 - Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione - Google Patents

Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Info

Publication number
ES3064009T3
ES3064009T3 ES18797367T ES18797367T ES3064009T3 ES 3064009 T3 ES3064009 T3 ES 3064009T3 ES 18797367 T ES18797367 T ES 18797367T ES 18797367 T ES18797367 T ES 18797367T ES 3064009 T3 ES3064009 T3 ES 3064009T3
Authority
ES
Spain
Prior art keywords
fluorobenzofuran
dioxolo
indol
dione
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18797367T
Other languages
English (en)
Spanish (es)
Inventor
Yamin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actuate Therapeutics Inc
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Application granted granted Critical
Publication of ES3064009T3 publication Critical patent/ES3064009T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES18797367T 2017-10-16 2018-10-16 Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Active ES3064009T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572603P 2017-10-16 2017-10-16
PCT/US2018/056083 WO2019079299A1 (en) 2017-10-16 2018-10-16 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (1)

Publication Number Publication Date
ES3064009T3 true ES3064009T3 (en) 2026-04-22

Family

ID=64110166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18797367T Active ES3064009T3 (en) 2017-10-16 2018-10-16 Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Country Status (16)

Country Link
US (3) US11407759B2 (enExample)
EP (2) EP4740944A2 (enExample)
JP (2) JP7776258B2 (enExample)
KR (1) KR102891811B1 (enExample)
CN (1) CN111315748B (enExample)
AU (1) AU2018352384B2 (enExample)
CA (1) CA3074037A1 (enExample)
DK (1) DK3697794T3 (enExample)
ES (1) ES3064009T3 (enExample)
FI (1) FI3697794T3 (enExample)
IL (1) IL273920B2 (enExample)
MX (1) MX2020003431A (enExample)
PL (1) PL3697794T3 (enExample)
PT (1) PT3697794T (enExample)
WO (1) WO2019079299A1 (enExample)
ZA (1) ZA202002740B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003431A (es) * 2017-10-16 2020-07-29 Actuate Therapeutics Inc Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.
CN112437663A (zh) * 2018-05-17 2021-03-02 开动疗法公司 用β型糖原合酶激酶3抑制剂治疗特发性肺纤维化

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
FI3665176T3 (fi) 2017-08-11 2024-03-20 Actuate Therapeutics Inc 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja
MX2020003431A (es) * 2017-10-16 2020-07-29 Actuate Therapeutics Inc Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.

Also Published As

Publication number Publication date
ZA202002740B (en) 2025-12-17
JP2024001040A (ja) 2024-01-09
WO2019079299A1 (en) 2019-04-25
JP2020536944A (ja) 2020-12-17
IL273920B1 (en) 2025-03-01
IL273920B2 (en) 2025-07-01
KR20200100615A (ko) 2020-08-26
US12116374B2 (en) 2024-10-15
CN111315748B (zh) 2023-06-27
US20250115615A1 (en) 2025-04-10
AU2018352384A1 (en) 2020-05-21
KR102891811B1 (ko) 2025-11-28
PL3697794T3 (pl) 2026-04-07
US11407759B2 (en) 2022-08-09
IL273920A (en) 2020-05-31
US20220348591A1 (en) 2022-11-03
DK3697794T3 (da) 2026-02-02
CA3074037A1 (en) 2019-04-25
US20200239489A1 (en) 2020-07-30
EP3697794B1 (en) 2025-12-24
MX2020003431A (es) 2020-07-29
PT3697794T (pt) 2026-03-04
BR112020007538A2 (pt) 2020-09-24
CN111315748A (zh) 2020-06-19
JP7776258B2 (ja) 2025-11-26
EP4740944A2 (en) 2026-05-13
AU2018352384B2 (en) 2023-12-21
EP3697794A1 (en) 2020-08-26
FI3697794T3 (fi) 2026-02-10

Similar Documents

Publication Publication Date Title
EA202092580A1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
EA202092581A1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
BR112019025388A2 (pt) Suplemento de ração animal, composição de ração animal, usos de um suplemento de ração animal, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal
EP4628094A3 (en) BAFF-R ANTIBODIES AND THEIR USES
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA202090296A1 (ru) Спироциклические соединения и способы их получения и применения
WO2019089676A8 (en) Antagonists of the muscarinic acetylcholine receptor m4
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CO2018008444A2 (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001909A1 (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
EA202090312A1 (ru) Спироциклические соединения и способы их получения и применения
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
EP3604353A4 (en) PHOTOCURING COMPOSITION, BASE FOR DENTAL PROSTHESIS, AND DENTIST
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
ES3063712T3 (en) Compositions for treating neurodegenerative diseases
MX2024003249A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
BR112017016497A2 (pt) composições e métodos para metabolismo muscular melhorado
EP3879513A4 (en) RESIN COMPOSITION AND BIOLOGICAL MODEL WITH IT
BR112019001207A2 (pt) composição vaginal compreendendo uma combinação de estrogênio e vitamina d
ZA202002740B (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
CO2019002853A2 (es) Composiciones de tesofensina
MX384850B (es) Composiciones farmacéuticas de estradiol insertadas por vía vaginal y métodos.